Clinical Trials Directory

Trials / Unknown

UnknownNCT05270174

A Prospective, Multicenter Cohort Study of Urinary Exosome lncRNAs for Preoperative Diagnosis of Lymphatic Metastasis in Patients With Bladder Cancer

Status
Unknown
Phase
Study type
Observational
Enrollment
74 (estimated)
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Bladder cancer is one of the most frequent malignant tumors of the urinary system in China, seriously threatening the life safety of patients. The main treatment methods for bladder cancer include surgical resection, radiotherapy and chemotherapy, immunotherapy, and targeted therapy, among which surgical resection is still the only reliable radical treatment at present. Lymphatic metastasis is the main mode of metastasis of bladder cancer, and preoperative diagnosis is of great significance to determine whether radical surgical treatment can be performed for some patients with advanced bladder cancer. Recent studies reveal that exosomes, as key signaling molecules in the tumor microenvironment, have been confirmed to be associated with various tumor progressions. Our previous study showed that lncRNA-ELNAT1 highly expressed in urine exosomes of bladder cancer patients can promote lymphatic metastasis of bladder cancer by inducing lymphatic angiogenesis, and is associated with poor prognosis of patients. However, whether exosome ELNAT1 can be used as an independent preoperative predictor of lymph node metastasis of bladder cancer needs to be explored in further clinical trials, and this study will further clarify the association between the two. In this study, urine exosomes were collected from positive and negative control patients with lymph node metastasis of bladder cancer, and the ROC curve was statistically analyzed and fitted to determine whether exosome ELANT1 could be used as an independent predictor of lymph node metastasis of bladder cancer.

Detailed description

1. According to the selection criteria. Bladder cancer patients with informed consent in the study were first included. 2. The patients with indications of radical cystectomy were selected. 3. Urine samples were collected before radical cystectomy and exocrine bodies were extracted to analyze the expression level of ELNAT1 4. According to the postoperative lymph node pathological results, the above patients were further divided into two groups:lymphatic metastasis positive group and negative group. 5. We perform statistical analysis of urinary exosomal ELNAT1 to validate the performance of diagnosing lymphatic metastasis of bladder cancer

Conditions

Interventions

TypeNameDescription
OTHERno interventionno intervention

Timeline

Start date
2023-06-01
Primary completion
2025-01-01
Completion
2025-08-01
First posted
2022-03-08
Last updated
2023-02-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05270174. Inclusion in this directory is not an endorsement.